Health

Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer | Getty ImagesPresident Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some analysts. Trump told reporters earlier this month that his administration will begin implementing low pharmaceutical levies as early as Aug. 1 and increase the rate in about a year or 18 months. He has threatened to impose up to 200% tariffs on imported drugs.It is still unclear if he will follow through with that exact plan and tariff rate, which makes it difficult to fully assess how the policy will affect drugmakers and patients. Domestic drug manufacturing operations are also ...

The office building of international biopharmaceutical company AstraZeneca.Cfoto | Future Publishing | Getty ImagesA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.President Donald Trump has been pressuring pharmaceutical companies to lower U.S. drug costs, and it may be starting to work – at least on AstraZeneca. AstraZeneca has proposed price cuts to certain drugs in the U.S., its CEO Pascal Soriot told reporters on Tuesday, after the company's second-quarter revenue and earnings topped estimates. "We have made proposals of what we as a company believe could be done, which would actually entail rebalancing pricing with a reduction in the U.S.," Soriot s...

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty ImagesThe Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths.Both Moderna and BioNTech helped pioneer mRNA, or messenger RNA, technology. Moderna staked its entire identity around mRNA, while BioNTech saw it as one piece of a broader portfolio focused on immunology and oncology. The pandemic gave both companies a chance to prove mRNA's promise of using the body's own immune system to protect against viruses or treat diseases. Covid vaccines have generated roughly $45 billion in sales for each company, earning them each about $20 billion since their rollout ...

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024.Adam Glanzman | Bloomberg | Getty ImagesModerna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of the year. Moderna had approximately 5,800 full-time employees in 18 countries as of Dec. 31, 2024, according to its 2024 annual report. Shares of Moderna have dropped more than 20% this year. In May, the company reported first-quarter vaccine sales that missed Wall Street's estimates. Moderna is also navigating policy hurdles under Health and Human ...

CVS Health on Thursday reported second-quarter earnings and revenue that topped estimates and raised its adjusted profit outlook, as it sees strength in its retail pharmacy business and some improvement in its insurance unit. Shares of the retail drugstore chain jumped more than 1% on Thursday.The company now expects fiscal 2025 adjusted earnings of $6.30 to $6.40 per share, up from previous guidance of $6 to $6.20 per share. CVS also cut its GAAP earnings guidance, without disclosing additional details.In an interview, CVS CEO David Joyner said the quarterly beat and guidance hike is in part "a tribute to the work and the effort underway within Aetna," the company's insurer. He was referring to a "multiyear recovery effort" at Aetna, which has been grappling with higher medical costs in p...

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024.Nurphoto | Nurphoto | Getty ImagesEli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.Mounjaro met the study's main goal of showing that it wasn't any worse than Trulicity at treating people with Type 2 diabetes and established cardiovascular disease. Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes, who are twice as likely to have heart disease or stroke as those without the disease.The results come as Trulicity – also a...

U.S. President Donald Trump, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (DOGE) attend the "Making Health Technology Great Again" event in the East Room at the White House in Washington, D.C., U.S., July 30, 2025. Evelyn Hockstein | ReutersPresident Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.On Truth Social on Thursday, Trump posted individual letters he sent 17 drugmakers: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, G...

The Moderna logo is seen in Warsaw, Poland, on April 9, 2025.Jakub Porzycki | Nurphoto | Getty ImagesModerna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street's expectations for the second quarter as it works to cut costs.Shares of Moderna fell more than 9% on Friday.The biotech company now expects full-year revenue to come in between $1.5 billion and $2.2 billion, down $300 million at the top of that range. The results come a day after Moderna announced plans to slash 10% of its workforce, adding to a string of cost cuts as the company grapples with falling Covid vaccine sales and tries to bring more products to market. In an interview, Moderna Chief Financial Officer Jamey Mock said instead of shipping spring ...

The Hers app arranged on a smartphone in New York on Feb. 12, 2025.Gabby Jones | Bloomberg | Getty ImagesShares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue.Here's how the company did based on average analysts' estimates compiled by LSEG:Earnings per share: 17 cents adjusted vs. 15 cents expectedRevenue: $544.8 million vs. $552 million expectedRevenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.For its third qu...

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty ImagesPfizer on Tuesday hiked its full-year adjusted profit guidance on cost cuts and its strong business performance this year.The company also reported second-quarter results that topped Wall Street's estimates for the period, as revenue from its Covid products and some other drugs jumped.Shares of Pfizer rose more than 4% on Tuesday.Pfizer now expects full-year adjusted profit to come in between $2.90 and $3.10, up from previous guidance of $2.80 to $3 per share. The company maintained its 2025 revenue forecast of $61 billion to $64 billion."We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strat...